论文部分内容阅读
目的:探讨雌激素诱导蛋白pS2和增殖细胞核抗原Ki-67在子宫内膜癌组织中的表达及其与临床病理的关系。方法:采用免疫组化S-P法检测20例正常增生期子宫内膜、30例非典型增生、75例子宫内膜癌组织中pS2、Ki-67的表达。结果:pS2在正常增生期子宫内膜中不表达,在非典型增生和子宫内膜癌中表达分别为60·00%和76·00%,两两比较有显著性差异(P<0·05)。Ki-67在正常增生期子宫内膜仅有少量表达,在内膜非典型增生和子宫内膜癌中表达分别为33·33%和77·33%,两两比较均有显著差异(P<0·05)。pS2的表达与子宫内膜癌的组织学分级、临床分期、肌层浸润深度、淋巴转移有关(P<0·05),但与分化程度无关(P>0·05)。Ki-67的表达与分化程度、组织分级、临床分期、肌层浸润深度、淋巴转移均有关(P<0·05)。在内膜癌组织中pS2与Ki-67的表达呈负相关r=-0·763(P<0·05)。结论:pS2和Ki-67表达与子宫内膜癌的发病机制有关,并与其预后有关,可作为判断内膜癌预后的指标。
Objective: To investigate the expression of estrogen-inducible protein pS2 and proliferating cell nuclear antigen Ki-67 in endometrial carcinoma and its relationship with clinicopathology. Methods: The expressions of pS2 and Ki-67 in 20 cases of normal proliferative endometrium, 30 cases of atypical hyperplasia and 75 cases of endometrial carcinoma were detected by immunohistochemical S-P method. Results: pS2 was not expressed in the normal proliferative endometrium, and it was 60.00% and 76.00% in the atypical hyperplasia and endometrial carcinoma respectively, with significant difference (P <0.05) ). The expression of Ki-67 in normal proliferative endometrium was only a little, and it was 33.33% and 77.33% in endometrial dysplasia and endometrial carcinoma, respectively, with significant difference (P < 0 · 05). The expression of pS2 was correlated with the histological grade, clinical stage, depth of myometrial invasion and lymphatic metastasis (P <0.05), but not with the degree of differentiation (P> 0.05). The expression of Ki-67 was related to the degree of differentiation, histological grade, clinical stage, depth of myometrial invasion and lymphatic metastasis (P <0.05). The expression of pS2 and Ki-67 in endometrial carcinoma was negatively correlated (r = -0.763, P <0.05). Conclusion: The expressions of pS2 and Ki-67 are correlated with the pathogenesis of endometrial carcinoma and their prognosis, which may be used as an index to judge the prognosis of endometrial carcinoma.